Monte Buchsbaum

Last updated

Monte Buchsbaum is a Professor emeritus of Psychiatry and Radiology at the University of California at San Diego. [1] He was also the founder and editor in chief of Psychiatry Research and Psychiatry Research Neuroimaging from 1979 to 2019. [2] He is the son of Invertebrate Biologist and author Ralph Buchsbaum.

Imaging research

Buchsbaum is a pioneer in the use of neuroimaging technology to study psychiatric disorders. In the early 1980s he, along with David Ingvar, performed the first positron emission tomography (PET) studies of patients with schizophrenia at the National Institutes of Health (NIH) and the patients had reduced glucose metabolism in the frontal lobe, a pattern known as hypofrontality. [3] His research has led to him being called as an expert witness during criminal trials. [4]

Related Research Articles

<span class="mw-page-title-main">Positron emission tomography</span> Medical imaging technique

Positron emission tomography (PET) is a functional imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption. Different tracers are used for various imaging purposes, depending on the target process within the body. For example, 18
F
-FDG
is commonly used to detect cancer, NaF18
F
is widely used for detecting bone formation, and oxygen-15 is sometimes used to measure blood flow.

<span class="mw-page-title-main">Single-photon emission computed tomography</span> Nuclear medicine tomographic imaging technique

Single-photon emission computed tomography is a nuclear medicine tomographic imaging technique using gamma rays. It is very similar to conventional nuclear medicine planar imaging using a gamma camera, but is able to provide true 3D information. This information is typically presented as cross-sectional slices through the patient, but can be freely reformatted or manipulated as required.

A radioligand is a radioactive biochemical substance, in particular, a ligand that is radiolabeled. Radioligands are used for diagnosis or for research-oriented study of the receptor systems of the body, and for anti-cancer radioligand therapy.

<span class="mw-page-title-main">Neuroimaging</span> Set of techniques to measure and visualize aspects of the nervous system

Neuroimaging is the use of quantitative (computational) techniques to study the structure and function of the central nervous system, developed as an objective way of scientifically studying the healthy human brain in a non-invasive manner. Increasingly it is also being used for quantitative research studies of brain disease and psychiatric illness. Neuroimaging is highly multidisciplinary involving neuroscience, computer science, psychology and statistics, and is not a medical specialty. Neuroimaging is sometimes confused with neuroradiology.

<span class="mw-page-title-main">Nora Volkow</span> American physician

Nora Volkow is a Mexican-American psychiatrist. She is currently the director of the National Institute on Drug Abuse (NIDA), which is part of the National Institutes of Health (NIH).

Abass Alavi is an Iranian-American physician-scientist specializing in the field of molecular imaging, most notably in the imaging modality of positron emission tomography (PET). In August 1976, he was part of the team that performed the first human PET studies of the brain and whole body using the radiotracer [18F]Fluorodeoxyglucose (FDG). Alavi holds the position of Professor of Radiology and Neurology, as well as Director of Research Education in the Department of Radiology at the University of Pennsylvania. Over a career spanning five decades, he has amassed over 2,300 publications and 60,000 citations, earning an h-index of 125 and placing his publication record in the top percentile of scientists.

<span class="mw-page-title-main">PET-CT</span> Medical imaging method

Positron emission tomography–computed tomography is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed (co-registered) image. Thus, functional imaging obtained by PET, which depicts the spatial distribution of metabolic or biochemical activity in the body can be more precisely aligned or correlated with anatomic imaging obtained by CT scanning. Two- and three-dimensional image reconstruction may be rendered as a function of a common software and control system.

<span class="mw-page-title-main">Altanserin</span> Chemical compound

Altanserin is a compound that binds to the 5-HT2A receptor. Labeled with the isotope fluorine-18 it is used as a radioligand in positron emission tomography (PET) studies of the brain, i.e., studies of the 5-HT2A neuroreceptors. Besides human neuroimaging studies altanserin has also been used in the study of rats.

<span class="mw-page-title-main">DASB</span> Chemical compound

DASB, also known as 3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile, is a compound that binds to the serotonin transporter. Labeled with carbon-11 — a radioactive isotope — it has been used as a radioligand in neuroimaging with positron emission tomography (PET) since around year 2000. In this context it is regarded as one of the superior radioligands for PET study of the serotonin transporter in the brain, since it has high selectivity for the serotonin transporter.

Jeffrey H. Meyer is a scientist and professor working with mood and anxiety disorders using neuroimaging at the Department of Psychiatry, University of Toronto. He is currently the head of the Neurochemical Imaging Program in Mood and Anxiety Disorders in the Brain Health Imaging Centre at the Campbell Family Mental Health Research Institute and is working as a Senior Scientist in the General and Health Systems Psychiatry Division at the Centre for Addiction and Mental Health. He has also been awarded with the Tier 1 Canada Research Chair in the Neurochemistry of Major Depression.

<span class="mw-page-title-main">Setoperone</span> Chemical compound

Setoperone is a compound that is a ligand to the 5-HT2A receptor. It can be radiolabeled with the radioisotope fluorine-18 and used as a radioligand with positron emission tomography (PET). Several research studies have used the radiolabeled setoperone in neuroimaging for the studying neuropsychiatric disorders, such as depression or schizophrenia.

Anissa Abi-Dargham is an American psychiatrist and researcher. She is a psychiatry professor and vice-chair of research at Stony Brook University and professor emerita at the Columbia University College of Physicians and Surgeons.

<span class="mw-page-title-main">PET-MRI</span>

Positron emission tomography–magnetic resonance imaging (PET–MRI) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging.

<span class="mw-page-title-main">Brain positron emission tomography</span> Form of positron emission tomography

Brain positron emission tomography is a form of positron emission tomography (PET) that is used to measure brain metabolism and the distribution of exogenous radiolabeled chemical agents throughout the brain. PET measures emissions from radioactively labeled metabolically active chemicals that have been injected into the bloodstream. The emission data from brain PET are computer-processed to produce multi-dimensional images of the distribution of the chemicals throughout the brain.

Peter T. Fox is a neuroimaging researcher and neurologist at the University of Texas Health Science Center at San Antonio. He is a professor in the Department of Radiology with joint appointments in Radiology, Medicine, and Psychiatry. He is the founding director of the Research Imaging Institute.

<span class="mw-page-title-main">Hypofrontality</span>

Hypofrontality is a state of decreased cerebral blood flow (CBF) in the prefrontal cortex of the brain. Hypofrontality is symptomatic of several neurological medical conditions, such as schizophrenia, attention deficit hyperactivity disorder (ADHD), bipolar disorder, and major depressive disorder. This condition was initially described by Ingvar and Franzén in 1974, through the use of xenon blood flow technique with 32 detectors to image the brains of patients with schizophrenia. This finding was confirmed in subsequent studies using the improved spatial resolution of positron emission tomography with the fluorodeoxyglucose (18F-FDG) tracer. Subsequent neuroimaging work has shown that the decreases in prefrontal CBF are localized to the medial, lateral, and orbital portions of the prefrontal cortex. Hypofrontality is thought to contribute to the negative symptoms of schizophrenia.

<span class="mw-page-title-main">Rajendra Badgaiyan</span> American physician

Professor Rajendra D Badgaiyan is an Indian-American psychiatrist and cognitive neuroscientist. He is best known for developing a new neuroimaging technique for detection of acute changes in concentration of dopamine released in the live human brain during performance of a cognitive. behavioral or emotional task.

The neural efficiency hypothesis proposes that while performing a cognitive task, individuals with higher intelligence levels exhibit lower brain activation in comparison to individuals with lower intelligence levels. This hypothesis suggests that individual differences in cognitive abilities are due to differences in the efficiency of neural processing. Essentially, individuals with higher cognitive abilities utilize fewer neural resources to perform a given task than those with lower cognitive abilities.

Julie A. Fiez is a cognitive neuroscientist known for her research on the neural basis of speech, language, reading, working memory, and learning in healthy and patient populations. She is Professor of Psychology and Neuroscience at the Learning Research and Development Center and the Center for the Neural Basis of Cognition at the University of Pittsburgh. She is also Adjunct Faculty in the Department of Psychology at Carnegie Mellon University.

<span class="mw-page-title-main">Julie C. Price</span> American physicist and professor of radiology

Julie C. Price is an American medical physicist and professor of radiology at Massachusetts General Hospital (MGH), Harvard Medical School (HMS), as well as the director of PET Pharmacokinetic Modeling at the Athinoula A. Martinos Center at MGH. Price is a leader in the study and application of quantitative positron emission tomography (PET) methods. Prior to this, Price worked with Pittsburgh colleagues to lead the first fully quantitative pharmacokinetic evaluations of 11C-labeled Pittsburgh compound-B (PIB), one of the most widely used PET ligands for imaging amyloid beta plaques. As a principal investigator at MGH, Price continues work to validate novel PET methods for imaging biological markers of health and disease in studies of aging and neurodegeneration, including studies of glucose metabolism, protein expression, neurotransmitter system function, and tau and amyloid beta plaque burden.

References

  1. "UCSD Profiles: Monte Buchsbaum". UCSD . Retrieved 2018-02-12. He heads the new NeuroPET Center and leads an effort in developing an expanded research effort with positron emission tomography.
  2. "M.S. Buchsbaum: Editor-in-Chief, Psychiatry Research". Psychiatry Research . Retrieved 2018-02-12.
  3. Buchsbaum, Monte S. (1982). "Cerebral Glucography With Positron Tomography". Archives of General Psychiatry. 39 (3): 251–9. doi:10.1001/archpsyc.1982.04290030001001. ISSN   0003-990X. PMID   6978119.
  4. Kevin Davis (2017). The Brain Defense: Murder in Manhattan and the Dawn of Neuroscience in America's Courtrooms. Penguin books. ISBN   9780698183353 . Retrieved 2018-02-12.